Osama Hamdy is Medical Director of the Obesity Clinical Program, Director of the Inpatinet Diabetes Program, senior endocrinologist and clinical investigator at Joslin Diabetes Center in Boston and Assistant Professor of Medicine at Harvard Medical School. Dr. Hamdy research led to the first discovery that 7% weight reduction in obese patients with type 2 diabetes significantly improves vascular endothelial function and insulin sensitivity that may eventually prevent progression of atherosclerosis and coronary artery disease. Dr. Hamdy was co-investigator of two landmark NIH studies; “the Diabetes Prevention Program” and “the Look AHEAD Study”. In 2005, Dr. Hamdy founded the “Weight Achievement and Intensive Treatment-Why WAIT?” program at the Joslin Diabetes Center, which is the first model of intervention to demonstrate a sustained weight reduction and an improvement in cardiovascular risk factors for 5 years. Dr. Hamdy won the 2015 Michaela Modan Award from the American Diabetes Association for his work on diabetes weight management. Dr. Hamdy chaired the task force that developed the Joslin Nutrition Guidelines. He is also a member of the Nutrition Committees of many American societies and co-chaired the global task force that developed the Transcultural Diabetes Nutrition Alogrithm (tDNA). Dr. Hamdy was nominated by the Harvard Medical School for best mentor award of 2013 and was given the Compassionate Caregiver Award of the Kenneth Scwartz Center. Dr. Hamdy has more than 150 peer-reviewed original articles, reviews, chapters and conference abstracts. He is on the editorial board of several medical journals including US Endocrinology, Journal of Nutritional Disorders & Therapy and 2-times section editor of the Current Diabetes Report and is on the editorial review board of many scentific medical journals including JAMA, Diabetes Care, Lancet, Obesity Research and the Expert Opinions.